The
third Objective (IRF3) brings together promising scientists and clinicians from the University of Pennsylvania and the Rockefeller University to combine gene therapy strategies, independently tested in humans, with the
goal of engineering, growing, and administering
killer cells that are uniquely empowered to find and kill HIV - infected cells.